InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.495 0.482 (3,707.69%)+
Announcement
Release
8 Sep 2025 9:47AM
Price at Release
$0.013
Full Release
download
Summary
Alterity Therapeutics Limited announced a capital raising of A$20 million through a strategic placement of fully paid ordinary shares to professional investors. This move follows positive results from their Phase 2 clinical trials for ATH434 in Multiple System Atrophy, a neurodegenerative disease. The placement was priced at A$0.012 per share, with no options issued, aiming to support further clinical, regulatory activities, and general working capital. MST Financial Services Pty Ltd acted as the sole manager for the offering. The proceeds will enhance Alterity's efforts in advancing ATH434 with the US FDA and other agencies.
Key Points
  • Alterity raised A$20 million through a strategic placement.
  • The placement was priced at A$0.012 per share with a 7.7% discount.
  • Funds will be used for advancing clinical and regulatory activities for ATH434.
  • MST Financial Services Pty Ltd managed the offering.
  • Positive Phase 2 clinical trial results for ATH434 were released.
  • The placement strengthens Alterity's institutional register and balance sheet.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.